Bli medlem
Bli medlem

Du är här


BioStock: Immunicum's vision for the cancer therapy landscape

Two of the biggest challenges in oncology are hard-to-treat solid tumours and tumour recurrence. Swedish biotech Immunicum are on a mission to tackle both challenges through their two cell-based immunotherapy candidates, ilixadencel and DCP-001. BioStock takes a closer look at the cancer therapy landscape and how Immunicum plans to make an impact.

Read the article at (

This is a press release from BioStock - Connecting Innovation & Capital. (

Författare Cision